Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Receivables (2016 - 2025)

Historic Receivables for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $231.1 million.

  • Pediatrix Medical's Receivables fell 8427.39% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.1 million, marking a year-over-year decrease of 8427.39%. This contributed to the annual value of $288.5 million for FY2024, which is 7957.47% down from last year.
  • Pediatrix Medical's Receivables amounted to $231.1 million in Q3 2025, which was down 8427.39% from $239.0 million recorded in Q2 2025.
  • Pediatrix Medical's 5-year Receivables high stood at $1.6 billion for Q4 2022, and its period low was $231.1 million during Q3 2025.
  • Moreover, its 5-year median value for Receivables was $1.4 billion (2023), whereas its average is $1.1 billion.
  • Per our database at Business Quant, Pediatrix Medical's Receivables soared by 50093.15% in 2022 and then tumbled by 8427.39% in 2025.
  • Pediatrix Medical's Receivables (Quarter) stood at $1.5 billion in 2021, then grew by 10.44% to $1.6 billion in 2022, then dropped by 11.9% to $1.4 billion in 2023, then tumbled by 79.57% to $288.5 million in 2024, then fell by 19.89% to $231.1 million in 2025.
  • Its Receivables was $231.1 million in Q3 2025, compared to $239.0 million in Q2 2025 and $242.5 million in Q1 2025.